Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating
Collegium Pharmaceutical Inc COLL
$35.39
▼ -1.64%
($-0.59)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$35.71
Prev Close
$35.98
Day Range
$34.40 – $36.28
52W Range
$29.19 – $50.79
Market Cap
$1.15B
P/E (TTM)
15.31
Beta
0.77
EPS (TTM)
$1.88
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-05-07 |
| Shares Out. | 32,430,000 |
| Website | collegiumpharma.com/ ↗ |
| Phone | 17817133699 |
| Employees | 423 |
| Revenue | $193.5M |
| Gross Profit | $172.7M |
| Net Income | $14.5M |
| Free Cash Flow | $329.8M |
| Total Assets | $1.65B |
| Total Liabilities | $1.34B |
| Equity | $312.4M |
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Collegium Pharmaceutical Inc is a publicly traded company under the ticker symbol COLL on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)